Literature DB >> 22027878

Circulating neuregulin-1β levels vary according to the angiographic severity of coronary artery disease and ischemia.

Carrie Anna Geisberg1, Guisong Wang, Radwan N Safa, Holly M Smith, Brent Anderson, Xu-Yang Peng, Brian Veerkamp, David X Zhao, Dana Blakemore, Chang Yu, Douglas B Sawyer.   

Abstract

BACKGROUND: Coronary artery disease (CAD) is the leading killer in the United States. Patients with severe CAD and ischemia have worse prognosis. Therefore expansion of biomarker research, to identify at-risk individuals and explain the complex biology between cardiovascular growth factors and atherosclerosis is needed. Neuregulin-1β (NRG-1β) is a myocardial stress activated growth and survival factor released from endocardial and endothelial cells. NRG-1β is essential for cardiovascular development and a regulator of angiogenesis. We postulated that plasma and serum levels of NRG-1β would vary in relation to CAD severity and the presence of stress-induced ischemia.
METHODS: We measured serum and plasma levels of NRG-1β and vascular endothelial growth factor (VEGF) in 60 patients undergoing cardiac catheterization. CAD severity was calculated from angiographic results using a modified Duke jeopardy score.
RESULTS: Serum NRG-1β (sNRG-1β), plasma NRG-1β (pNRG-1β), serum VEGF, and plasma VEGF were detectable in the majority of patients. The pNRG-1β levels were approximately two-fold higher than sNRG-1β. Both sNRG-1β and pNRG-1β correlated inversely with CAD severity. pNRG-1β levels were statistically higher in patients with stress-induced ischemia denoted by a positive myocardial perfusion imaging study that correlated with angiographic findings (P=0.02).
CONCLUSION: Both sNRG-1β and pNRG-1β correlated inversely with angiographic severity of CAD. pNRG-1β levels were two-fold higher than serum and were higher in patients with stress-induced ischemia. Therefore we conclude that plasma is the optimal source for the further exploration of the biological significance of NRG-1β as a biomarker of CAD severity and ischemia.
© 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22027878      PMCID: PMC3217257          DOI: 10.1097/MCA.0b013e32834d3346

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  26 in total

1.  Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling.

Authors:  Yukio Kuramochi; Gregory M Cote; Xinxin Guo; Nathan K Lebrasseur; Lei Cui; Ronglih Liao; Douglas B Sawyer
Journal:  J Biol Chem       Date:  2004-09-21       Impact factor: 5.157

2.  Plasma cystatin C concentration reflects the severity of coronary artery disease in patients without chronic kidney disease.

Authors:  Arihiro Kiyosue; Yasunobu Hirata; Jiro Ando; Hideo Fujita; Toshihiro Morita; Masao Takahashi; Daisuke Nagata; Takahide Kohro; Yasushi Imai; Ryozo Nagai
Journal:  Circ J       Date:  2010-09-29       Impact factor: 2.993

3.  Neuregulin-1alpha and beta isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro.

Authors:  Gregory M Cote; Thomas A Miller; Nathan K Lebrasseur; Yukio Kuramochi; Douglas B Sawyer
Journal:  Exp Cell Res       Date:  2005-09-26       Impact factor: 3.905

4.  Vascular endothelial growth factor (VEGF) plasma concentrations in coronary artery disease.

Authors:  H F Alber; M Frick; J Dulak; J Dörler; R-H Zwick; W Dichtl; O Pachinger; F Weidinger
Journal:  Heart       Date:  2005-03       Impact factor: 5.994

5.  Heregulin, cysteine rich-61 and matrix metalloproteinase 9 expression in human carotid atherosclerotic plaques: relationship with clinical data.

Authors:  F Sigala; S Georgopoulos; E Papalambros; D Chasiotis; G Vourliotakis; A Niforou; A Kotsinas; N Kavantzas; E Patsouris; V G Gorgoulis; E Bastounis
Journal:  Eur J Vasc Endovasc Surg       Date:  2006-06-13       Impact factor: 7.069

6.  Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk.

Authors:  Katrien Lemmens; Vincent F M Segers; Marc Demolder; Gilles W De Keulenaer
Journal:  J Biol Chem       Date:  2006-05-11       Impact factor: 5.157

7.  Serum Neuregulin-1beta as a Biomarker of Cardiovascular Fitness.

Authors:  Vaibhav Moondra; Satyam Sarma; Tracy Buxton; Radwan Safa; Gregory Cote; Thomas Storer; Nathan K Lebrasseur; Douglas B Sawyer
Journal:  Open Biomark J       Date:  2009

8.  Prognostic value of a coronary artery jeopardy score.

Authors:  R M Califf; H R Phillips; M C Hindman; D B Mark; K L Lee; V S Behar; R A Johnson; D B Pryor; R A Rosati; G S Wagner
Journal:  J Am Coll Cardiol       Date:  1985-05       Impact factor: 24.094

9.  Evidence for association of coronary sinus levels of hepatocyte growth factor and collateralization in human coronary disease.

Authors:  Daniel J Lenihan; Abdulfatah Osman; Vissa Sriram; Julius Aitsebaomo; Cam Patterson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-01-09       Impact factor: 4.733

10.  Neuregulin-1 reduces ischemia-induced brain damage in rats.

Authors:  Woei-Cherng Shyu; Shinn-Zong Lin; Ming-Fu Chiang; Hui-I Yang; Peterus Thajeb; Hung Li
Journal:  Neurobiol Aging       Date:  2004-08       Impact factor: 4.673

View more
  21 in total

Review 1.  Neuregulin-1 signaling in the pathogenesis of chemotherapy-induced heart failure.

Authors:  Carrie Geisberg Lenneman
Journal:  Curr Heart Fail Rep       Date:  2014-06

2.  Neuregulin-1β induces proliferation, survival and paracrine signaling in normal human cardiac ventricular fibroblasts.

Authors:  Annet Kirabo; Sergey Ryzhov; Manisha Gupte; Seng Sengsayadeth; Richard J Gumina; Douglas B Sawyer; Cristi L Galindo
Journal:  J Mol Cell Cardiol       Date:  2017-03-03       Impact factor: 5.000

Review 3.  Signalling between microvascular endothelium and cardiomyocytes through neuregulin.

Authors:  Emily M Parodi; Bernhard Kuhn
Journal:  Cardiovasc Res       Date:  2014-01-29       Impact factor: 10.787

4.  Circulating neuregulin during the transition from stage A to stage B/C heart failure in a breast cancer cohort.

Authors:  Carrie A Geisberg; Wissam M Abdallah; Monica da Silva; Cheri Silverstein; Holly M Smith; Vandana Abramson; Ingrid Mayer; Julie Means-Powell; Darla Freehardt; Brenda White; Daniel Lenihan; Douglas B Sawyer
Journal:  J Card Fail       Date:  2013-01       Impact factor: 5.712

5.  High ErbB3 activating activity in human blood is not due to circulating neuregulin-1 beta.

Authors:  Emmanuel Boateng; Joanne T deKay; Sarah M Peterson; Jacob Boles; Nathan Pinnette; Mary W Sorcher; Michael P Robich; Douglas B Sawyer; Sergey Ryzhov
Journal:  Life Sci       Date:  2020-04-03       Impact factor: 5.037

6.  Effects of endogenous serum neuregulin-1β on morbidity and mortality in patients with heart failure and left ventricular systolic dysfunction.

Authors:  Jennifer Miao; Shi Huang; Yan Ru Su; Carrie A Lenneman; Meera Wright; Frank E Harrell; Douglas B Sawyer; Daniel J Lenihan
Journal:  Biomarkers       Date:  2018-08-17       Impact factor: 2.658

7.  Expression and secretion of neuregulin-1 in cardiac microvascular endothelial cells treated with angiogenic factors.

Authors:  Chengqiang Wu; Chun Gui; Lang Li; Yiheng Pang; Zhongli Tang; Jing Wei
Journal:  Exp Ther Med       Date:  2018-01-30       Impact factor: 2.447

Review 8.  Neuregulin as a heart failure therapy and mediator of reverse remodeling.

Authors:  Cristi L Galindo; Sergey Ryzhov; Douglas B Sawyer
Journal:  Curr Heart Fail Rep       Date:  2014-03

Review 9.  Neuregulin in cardiovascular development and disease.

Authors:  Oghenerukevwe Odiete; Michael F Hill; Douglas B Sawyer
Journal:  Circ Res       Date:  2012-10-26       Impact factor: 17.367

Review 10.  Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.

Authors:  Joerg Herrmann; Eric H Yang; Cezar A Iliescu; Mehmet Cilingiroglu; Konstantinos Charitakis; Abdul Hakeem; Konstantinos Toutouzas; Massoud A Leesar; Cindy L Grines; Konstantinos Marmagkiolis
Journal:  Circulation       Date:  2016-03-29       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.